A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
Clinical manifestations and outcomes of severe warfarin overanticoagulation: from the EWA study




Julkaisun tekijät: Jaakkola Samuli, Nuotio Ilpo, Kiviniemi Tuomas, Virtanen Raine, Virta Aku, Airaksinen K. E. Juhani
Kustantaja: Taylor & Francis
Julkaisuvuosi: 2018
Journal: Annals of Medicine
Tietokannassa oleva lehden nimi: Annals of medicine
Lehden akronyymi: Ann Med
Volyymi: 50
Julkaisunumero: 2
Sivujen määrä: 8
ISSN: 1365-2060

Tiivistelmä

Introduction: Severe warfarin overanticoagulation is a risk factor for bleeding, but there is little information on its manifestations, prognosis and factors affecting the outcome. We describe the manifestations and clinical outcomes of severe warfarin overanticoagulation in a large group of patients with atrial fibrillation (AF).

Material and methods: All international normalized ratio (INR) samples (n = 961,431) in the Turku University Hospital region between 2003 and 2015 were screened. A total of 412 AF patients with INR ≥9 were compared to 405 patients with stable warfarin anticoagulation for AF. Electronic patient records were manually reviewed to collect comprehensive data.

Results: Of the 412 patients with INR ≥9, bleeding was the primary manifestation in 105 (25.5%). Non-bleeding symptoms were recorded in 165 (40.0%) patients and 142 (34.5%) had no symptoms. A total of 17 (16.2%) patients with a bleed and 67 (21.8%) without bleeding died within 30 days after the event. Intracranial haemorrhage strongly predicted death within 30 days. Other significant predictors were non-bleeding symptoms, active malignancies, recent bleed, history of myocardial infarction, older age, renal dysfunction and a recent treatment episode.

Conclusions: Bleeds are not the major determinant of the poor prognosis in severe overanticoagulation, as coincidental INR ≥9 findings also associate with high mortality.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2019-15-03 at 09:48